In our present study, we focused on the preparation and evaluation of a stable nano-formulation of small molecule drug rottlerin encapsulated within PLGA (Poly(D, L-lactic-co-glycolic acid)) nanoparticles. The endeavor was to increase therapeutic efficacy of rottlerin against, and drug delivery to, pancreatic cancer cells. Size and morphology analysis by Dynamic light scattering (DLS) and Scanning electron microscopy (SEM) revealed the average size of nanoparticles prepared was 150–300 nm. In vitro drug release study confirmed the suitability of PLGA nanoparticles as a matrix for controlled release of rottlerin. In vitro cytotoxicity assay in MiaPaCa-2 cells showed dose dependent and preferential toxicity on pancreatic cancer cells compared to normal Vero cells. Furthermore, apoptosis mediated cell death was higher in the rottlerin nanoparticles treated cells and there was also a significant delay in cancer cell migration along with reduction in colony formation. Henceforth the study prospects that the potential therapeutic value of rottlerin against pancreatic cancer can have added advantage through its nanoformulation using a suitable polymeric carrier.
S. K.S., V.-K., L., and Shantikumar V Nair, “Sustained Release of Rottlerin Encapsulated within Poly(D, L-lactic-co-glycolic acid) Nanoparticles Inhibits Migration and Clonogenicity in Pancreatic cancer Cells”, Journal of Nanoscience and Nanotechnology, vol. 16, 2016.